Summary & Overview
HCPCS Level II Q4220: Bellacell hd or Surederm, Per Square Centimeter
HCPCS Level II code Q4220 designates Bellacell hd or Surederm billed per square centimeter as an add-on supply in addition to a primary procedure. The code identifies unit-based use of a dermal product used during reconstructive or dermatologic procedures, and matters nationally where itemized biomaterial billing impacts procedure-level cost reporting and payer coverage decisions.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for the product, how the code functions as an add-on supply, and what to expect in payer considerations. The publication summarizes typical sites of service, common billing modifiers, and areas where policy clarification is often needed.
This report provides benchmarks and policy-focused highlights: description of the code and its service implications, typical reimbursement handling by major payers, and operational notes for facility and professional billing. The document also flags areas with limited publicly available guidance and directs readers to available payer-specific policies when applicable. Data not available in the input is noted where relevant.
Billing Code Overview
HCPCS Level II code Q4220 describes Bellacell hd or surederm, per square centimeter as an add-on product billed separately in addition to a primary procedure. The code represents a unit-based supply or material used during a clinical procedure where coverage is itemized and charged per square centimeter.
Service Type: Injectable or implantable dermal product / procedural add-on
Typical Site of Service: Outpatient procedural settings such as ambulatory surgery centers, physician offices, and hospital outpatient departments
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult seeking surgical repair of a full-thickness facial or body soft-tissue defect requiring placement of a biologic dermal matrix graft measured and billed per square centimeter. The patient often presents after tumor extirpation (e.g., excision of a skin malignancy), traumatic wound debridement, or revision of a prior reconstructive procedure with insufficient native dermis. The surgical workflow includes preoperative evaluation by a dermatologic surgeon or plastic surgeon, lesion excision or wound bed preparation under local or general anesthesia, hemostasis and sizing of the defect, placement and securement of the dermal substitute (billed with Q4220 per square centimeter as an add-on to the primary procedure), and layered wound closure or application of a skin graft as indicated. Postoperative care includes dressing changes, wound inspections, and scheduled follow-up visits to monitor graft integration and healing. Typical sites of service are outpatient ambulatory surgical centers and hospital outpatient departments; anesthesia may be local, monitored anesthesia care, or general depending on case complexity.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No physician or practitioner of record | Rarely used; indicates no physician is identified on the claim when applicable under payer rules. |